Chartausbruch bei ORCH (935196).. !!! - 500 Beiträge pro Seite

[tdwzb]

Orchid Biosciences - ORCH - 935196

akt.: etwa 1,60 - 1,65€ bzw. 2,05$
1. KZ: 2,5$

traumhafter CHART:

[heikekarina]

[onickerl]

[tdwzb]

2,14$

[hajoberg]

Freunde, bei +50% lohnt sich doch wohl der Einstieg nicht mehr, oder??
Hajo

[Paepstin]

Hajo,
wenn FFM heute vermutlich mit 2,15 schließt? Wo ist dein Problem?
Päpstin

[tdwzb]

2,25$

[powerautomation]

@ all

noch kann man günstig unter pari rein:

2,21 $ = 1,75 €

Gruß

P WER

[tdwzb]

2,27$

[mfierke]

[jetti]

achtet auch bitte auf 675548

[suncomesout]

Ring frei zur nächsten Runde?
TEPNEL COMPLETES ACQUISTION OF ORCHID`S DIAGNOSTICS UNIT




PRINCETON, N.J., and MANCHESTER, U.K., Jan. 22, 2004 - Orchid BioSciences, Inc. (Nasdaq: ORCH) and Tepnel Life Sciences PLC (AIM: TED) today announced that Tepnel has completed its acquisition of certain assets and liabilities of Orchid’s diagnostics unit. The diagnostics unit, which will now operate as Tepnel Lifecodes Corporation in the U.S. and Tepnel Diagnostics Ltd. in Europe, provides systems, consumables and services for HLA testing for organ transplantation, and genetic screening for disease predisposition, as well as certain related support services.

Under the terms of the agreement, Tepnel has acquired the product and services business of Orchid Diagnostics unit in the U.S., the U.K. and Belgium, including its LifeMatch™ system and consumable product line for HLA testing and its Elucigene™ product line for testing of certain genetic diseases, as well as certain liabilities of the diagnostics business, for $3.45 million in cash, subject to a further adjustment in respect of net assets once completion accounts have been prepared and agreed by both parties. Orchid and Tepnel agreed among other things, to a revised purchase price of $3.45 million to reflect changing market conditions. Tepnel has taken control of the facilities formerly occupied by Orchid’s diagnostic unit in Stamford, Connecticut and Brussels, Belgium, and has indicated its intention to retain all of the diagnostics unit’s employees.

About Tepnel Life Sciences PLC
Tepnel is a UK-based international life sciences instrumentation and services company with a ‘tri-polar’ strategy focused on providing the biomedical industry with high-throughput automated DNA purification systems, manual DNA purification kits and reagents, as well as scientific services for nucleic acid purification, drug analysis, genotyping and genetically modified foods. Tepnel was founded in 1992 to exploit DNA technology generated at UMIST (University of Manchester Institute of Science and Technology) and is quoted on the AIM market of the London Stock Exchange (AIM: TED).


SCO

[suncomesout]

Aktuelle Entwicklung:

Orchid BioSciences Announces Conversion of Preferred Stock and Provides Financial Guidance Update


PRINCETON, N.J., Feb. 10 /PRNewswire-FirstCall/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH) today announced that all of its outstanding convertible preferred stock has been converted into common stock. As a result, Orchid had approximately 94.7 million common shares outstanding as of February 9, 2004. Additionally, Orchid provided an update to its financial guidance for 2003 and 2004.

"In view of the many near-term growth opportunities facing Orchid, I believe the next step in our restructuring is to further strengthen our capital structure in order to better position the company for profitable growth," said Paul J. Kelly, M.D., chief executive officer of Orchid. "With completion of this initial phase of our capital restructuring effort, we look forward to the next phases, which we expect will include our proposed reverse stock split and, at an appropriate time, raising additional capital to help fund Orchid`s next phase of growth."

Orchid re-affirmed and expanded its financial guidance for the full year 2003 and for 2004:

2003 Financial Guidance Update
-- Orchid continues to expect top-line revenues of approximately $50
million for the full year 2003.
-- Orchid estimates that its 2003 year-end free cash balance will be
approximately $10 million, which includes $1 million of the $3.45
million purchase price paid to Orchid in connection with the sale of
its Diagnostics unit. This estimate differs from the company`s
previous guidance of $11 million to $13 million because the
transaction closed in January 2004 and as a result the full purchase
price could not be recorded in 2003.
-- Orchid expects its average gross margin to be in the low-to-mid 40
percent range for the full year 2003.

2004 Financial Guidance Update
-- Orchid expects an increase in its 2004 top-line revenues of
approximately 20 percent over its expected 2003 top-line revenues.
-- Orchid expects its 2004 average gross margin to improve by
approximately 2 to 4 percentage points over its expected 2003 gross
margins.
-- Orchid expects its full year 2004 total operating expenses to decrease
by approximately 10 percent compared to its expected total operating
expenses for 2003.
-- Orchid continues to expect to achieve positive cash flows from
operations in the first half of 2004.
-- Orchid expects to achieve positive operating income for the full year
2004.

Fourth Quarter and Full Year 2003 Financial Results

Orchid`s fourth quarter and full year 2003 financial results are scheduled to be released on Thursday, February 26, 2004, and an investor conference call with management will be held that morning to discuss the financial results and recent operating highlights as well as 2004 guidance. The company will announce the call details on or about February 19, 2004.

Reverse Stock Split

As previously announced, Orchid is seeking shareholder approval to implement a reverse stock split ranging from 1-for-3 shares to 1-for-7 shares. A Special Meeting of Shareholders will be held on February 27, 2004 to consider this proposal.

SCO

[suncomesout]

Wow!
Topstocks der letzten 24 Stunden

1. PROVIDENTIAL HLDGS ... 100
2. TOURNIGAN GOLD COR 69
3. NEWTECH RESOURCES LT... 39
4. DEUTSCHE ENTERTAINME... 34
5. QSC AG 32
6. UNIVERSAL EXPRESS IN... 22
7. MLP AG 21
8. IM INTERNATIONALMEDI... 21
9. ORCHID BIOSCIENCES, ... 20
10. OBDUCAT AB 19
11. WCM BETEILIGUNGS-UND... 16
12. FREENET.DE AG 16
13. Realtos Grund- und B... 16
14. AMBRI LTD 16
15. MORPHOSYS AG 14



SCO

[suncomesout]

Und nun schon auf Platz 4..
1. PROVIDENTIAL HLDGS ... 106
2. TOURNIGAN GOLD COR 70
3. NEWTECH RESOURCES LT... 40
4. ORCHID BIOSCIENCES, ... 36

SCO

[Paepstin]

Topstocks der letzten 24 Stunden

1. PROVIDENTIAL HLDGS ... 109
2. TOURNIGAN GOLD COR 70
3. ORCHID BIOSCIENCES, ... 48
4. NEWTECH RESOURCES LT... 41


Juchuuuuuuu, Ozonloch!
Päpstin